Fmr LLC Buys 566,328 Shares of Cibus, Inc. (NASDAQ:CBUS)

Fmr LLC lifted its stake in shares of Cibus, Inc. (NASDAQ:CBUS) by 16.9% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 3,913,279 shares of the company’s stock after purchasing an additional 566,328 shares during the quarter. Fmr LLC owned 14.79% of Cibus worth $12,757,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors have also recently added to or reduced their stakes in the company. SG Americas Securities LLC acquired a new position in shares of Cibus in the 3rd quarter worth approximately $33,000. Charles Schwab Investment Management Inc. lifted its position in shares of Cibus by 14.6% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 49,285 shares of the company’s stock worth $161,000 after purchasing an additional 6,276 shares during the period. FineMark National Bank & Trust lifted its position in shares of Cibus by 24.3% in the 2nd quarter. FineMark National Bank & Trust now owns 20,488 shares of the company’s stock worth $202,000 after purchasing an additional 4,000 shares during the period. Squarepoint Ops LLC acquired a new position in shares of Cibus in the 2nd quarter worth approximately $214,000. Finally, Rhumbline Advisers acquired a new position in shares of Cibus in the 2nd quarter worth approximately $221,000. 33.81% of the stock is owned by institutional investors.

Cibus Stock Down 5.5 %

Cibus stock opened at $4.13 on Thursday. The firm’s fifty day moving average is $4.11 and its 200 day moving average is $6.76. Cibus, Inc. has a 12-month low of $2.86 and a 12-month high of $23.18. The company has a market capitalization of $109.28 million, a PE ratio of -0.18 and a beta of 1.86.

Analysts Set New Price Targets

A number of research analysts recently issued reports on CBUS shares. Canaccord Genuity Group reiterated a “buy” rating and set a $20.00 target price on shares of Cibus in a research report on Tuesday, October 22nd. HC Wainwright reiterated a “buy” rating and set a $25.00 target price on shares of Cibus in a research report on Monday, November 11th. Finally, Alliance Global Partners dropped their target price on shares of Cibus from $25.00 to $23.50 and set a “buy” rating on the stock in a research report on Tuesday, September 24th.

Cibus Profile

Cibus, Inc, a agricultural biotechnology company, develops and licenses plant traits to seed companies for royalties. The company primarily focus on trait productivity in two areas, including productivity traits that enable farmers to have higher yields and reduce the use of the crop protection chemicals and fertilizers; and sustainable ingredients that enable corporations to replace ingredients that are fossil fuel based or whose production results in increased greenhouse gases.